Ketamin in therapy of pharmacoresistent depressions in patients with double diagnosis (naturalistic study)

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Pharmacotherapy of depression based on a monoaminergic model in many cases is not enough effective. In this regard the ketamine treatment results of pharmacoresistant depression by subanaesthetic doses, including the patients with double diagnosis, are of interest. Method: in an open label naturalistic non-randomized trial, 12 patients with non-psychotic treatment-resistant depression (10 of whom had concomitant addictive disorder), 6 sessions of ketamine therapy (0.5 - 0.75 mg/kg intravenously) were undertaken. Clinical and psychometric (Beck scale, visual analogue scale and scale of general clinical impression) assessment were used. Statistical processing - general linear model and nonparametric criterion. Results: the effectiveness of therapy was noted in 11 of 12 respondents, and in 7 ones the improvement was qualified as significant. The total scores of the scales applied corresponded to 50% reduction of depressive symptoms (p≤0.05). Conclusions: ketamine proved to be an effective and safe method of the fast achieving therapeutic effect in patients with therapeutically-resistant depression. However insufficiently representative sample, the lack of a control group and the mechanism of randomization and the open nature of the study limit the wide extrapolation of the results.

Full Text

Restricted Access

About the authors

Mikhail L. Zobin

Center of Transformational Therapy, Dobrota

Author for correspondence.
Montenegro, 85330, Kotor


  1. Aitken R.C.B. A growing age of measurement of feelings. – University Department of Psyhiatry, Roal Edinburgh Hospital, Edinburgh. Proc. roy. Soc. Med. Volume 62 October 1969.
  2. Andrews P.W., Thomson J.A.Jr., Amstadter A., Neale M.C. Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good // Front. Psychol. 2012. Vol. 3. ID 117.
  3. Beck A.T. et al. An Inventory for Measuring Depres-sion // Archives of general psychiatry. 1961. Vol. 4, № 6. P. 561‒571.
  4. Cougle J.R., Hakes J.K., Macatee R.J. et al. Probability and correlates of dependence among regular users of alcohol, nicotine, cannabis, and cocaine: concurrent and prospective analyses of the National Epidemiologic Survey on Alcohol and Related Conditions // J Clin Psychiatry. 2016 Apr. Vol. 77(4). P. e444‒450.
  5. Coupland C.A., Dhiman P., Barton G. et al. A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database // Health Technol Assess. 2011 Aug. Vol. 15(28). P. 1‒202.
  6. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization, 2017. Licence: CC BY-NC-SA 3.0 IGO.
  7. Fond G., Loundou A., Rabu C. et al. Ketamine admi-nistration in depressive disorders: a systematic review and meta-analysis // Psychopharmacology (Berl). 2014 Sep. Vol. 231(18). P. 3663‒3676.
  8. Gaynes B.N., Warden D., Trivedi M.H. et al. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression // Psychiatr Serv. 2009. Vol. 60. P. 1439‒1445.
  9. Guy W. Clinical Global Impression / ECDEU Assessment Manual for Psychopharmacology, revised National Institute of Mental Health, Rockville, MD, U.S., 1976.
  10. Jansen K.L., Darracot-Cankovic R. The nonmedical use of ketamine, part two: A review of problem use and depen-dence // J Psychoactive Drugs. 2001 Apr-Jun. Vol. 33(2). P. 151‒158.
  11. Kalsi S.S., Wood D.M., Dargan P.I. The epidemiology and patterns of acute and chronic toxity associated with recreational ketamine use // Health Threats Journal. 2011 Apr. Vol. 15 (4). P. 7107.
  12. Kolp E., Friedman H., Krupitsky E. et al. Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications In The Ketamine Papers: Science, Therapy, and Transformation. [Ed. by P. Wolfson and G. Hartelius]. 2016 MAPS. P. 97‒197.
  13. Krupitsky E., Burakov A., Romanova T. et al. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up // J Subst Abuse Treat. 2002 Dec. Vol. 23(4). P. 273‒283.
  14. Krupitsky E.M., Burakov A.M., Dunaevsky I.V. et al. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence // J Psy- choactive Drugs. 2007 Mar. Vol. 39(1). P. 13‒19.
  15. Krupitsky E.M., Grinenko A.Y. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research // J Psychoactive Drugs. 1997 Apr-Jun. Vol. 29(2). P. 165‒183.
  16. Lee E.E., Della Selva M.P., Liu A., Himelhoch S. Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis // Gen Hosp Psychiatry. 2015 Mar-Apr. Vol. 37(2). P. 178‒184.
  17. Majić T., Schmidt T., Gallinat J. Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? // Journal of Psychopharmacology. 2015. Vol. 29(3). P. 241–253.
  18. Malhi G.S., Byrow Y., Cassidy F. et al. Ketamine: stimulating antidepressant treatment? // B J Psych Open. 2016 May 11. Vol. 2(3). P. e5‒e9.
  19. McAndrew A., Lawn W., Stevens T. et al. A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial // Trials. 2017. Vol. 18. P. 159.
  20. McGirr A., Berlim M.T., Bond D.J. et al. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes // Psychol Med. 2015 Mar. Vol. 45(4). P. 693‒704.
  21. Morgan C.J., Curran H.V. Independent Scientific Committee on Drugs. Ketamine use: a review // Addiction. 2012 Jan. Vol. 107(1). P. 27‒38.
  22. Naughton M., Clarke G., O’Leary O.F. et al. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action // J Affect Disord. 2014 Mar. Vol. 156. P. 24‒35.
  23. Newport D.J., Carpenter L.L., McDonald W.M. et al. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression // Am J Psychiatry. 2015 Oct. Vol. 172(10). P. 950‒966.
  24. Rush A.J., Trivedi M.H., Wisniewski S.R. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report // Am J Psychiatry. 2006. Vol. 163. P. 1905–1917.
  25. Ryan W., Marta C., Koek R. Ketamine, Depression and Current Research: A Review of the Literature. In The Ketamine Papers: Science, Therapy, and Transformation [Ed. by P. Wolfson and G. Hartelius]. 2016 MAPS. P. 199‒274.
  26. Serafini G., Howland R.H., Rovedi F. et al. The role of ketamine in treatment-resistant depression: a systematic review // Curr Neuropharmacol. 2014 Sep. Vol. 12(5). P. 444‒461.
  27. The Global Burden of Disease 2004 Update. WHO, 2008.
  28. Warden D., Rush A.J., Trivedi M.H. et al. The STAR*D Project results: a comprehensive review of findings // Curr Psychiatry Rep. 2007 Dec. Vol. 9(6). P. 449‒459.
  29. Zarate C.A.Jr, Singh J.B., Carlson P.J. et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression // Arch Gen Psychiatry. 2006 Aug. Vol. 63(8). P. 856‒864.

Supplementary files

Supplementary Files
1. Fig. 1

Download (77KB)

Copyright (c) 2023 Eco-Vector

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 75562 от 12 апреля 2019 года.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies